Delayed Response After Confirmed Progression (DR) and Other Unique Immunotherapy-Related Treatment Concepts in Cutaneous Squamous Cell Carcinoma
Non-melanoma skin cancers are one of the most common cancers diagnosed worldwide, with the highest incidence in Australia and New Zealand. Systemic treatment of locally advanced and metastatic cutaneous squamous cell carcinomas has been revolutionized by immune checkpoint inhibition with PD-1 blocka...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-04-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.656611/full |
| _version_ | 1819121696072794112 |
|---|---|
| author | Annette M. Lim Annette M. Lim Karda Cavanagh Rodney J. Hicks Luke McLean Michelle S. Goh Angela Webb Danny Rischin Danny Rischin |
| author_facet | Annette M. Lim Annette M. Lim Karda Cavanagh Rodney J. Hicks Luke McLean Michelle S. Goh Angela Webb Danny Rischin Danny Rischin |
| author_sort | Annette M. Lim |
| collection | DOAJ |
| description | Non-melanoma skin cancers are one of the most common cancers diagnosed worldwide, with the highest incidence in Australia and New Zealand. Systemic treatment of locally advanced and metastatic cutaneous squamous cell carcinomas has been revolutionized by immune checkpoint inhibition with PD-1 blockade. We highlight treatment issues distinct to the management of the disease including expansion of the traditional concept of pseudoprogression and describe delayed responses after immune-specific response criteria confirmed progressive disease with and without clinical deterioration. We term this phenomenon “delayed response after confirmed progression (DR)”. We also discuss the common development of second primary tumors, heterogeneous disease responses, and expanding clinical boundaries for immunotherapy use. |
| first_indexed | 2024-12-22T06:40:39Z |
| format | Article |
| id | doaj.art-bb6e9bb3f376428e9f43116586aea575 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-22T06:40:39Z |
| publishDate | 2021-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-bb6e9bb3f376428e9f43116586aea5752022-12-21T18:35:26ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-04-011110.3389/fonc.2021.656611656611Delayed Response After Confirmed Progression (DR) and Other Unique Immunotherapy-Related Treatment Concepts in Cutaneous Squamous Cell CarcinomaAnnette M. Lim0Annette M. Lim1Karda Cavanagh2Rodney J. Hicks3Luke McLean4Michelle S. Goh5Angela Webb6Danny Rischin7Danny Rischin8Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, AustraliaSir Peter MacCallum Department of Oncology, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, VIC, AustraliaDepartment of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC, AustraliaDepartment of Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, AustraliaDepartment of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, AustraliaDepartment of Dermatology, Peter MacCallum Cancer Centre, Melbourne, VIC, AustraliaDepartment of Plastic Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC, AustraliaDepartment of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, AustraliaSir Peter MacCallum Department of Oncology, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, VIC, AustraliaNon-melanoma skin cancers are one of the most common cancers diagnosed worldwide, with the highest incidence in Australia and New Zealand. Systemic treatment of locally advanced and metastatic cutaneous squamous cell carcinomas has been revolutionized by immune checkpoint inhibition with PD-1 blockade. We highlight treatment issues distinct to the management of the disease including expansion of the traditional concept of pseudoprogression and describe delayed responses after immune-specific response criteria confirmed progressive disease with and without clinical deterioration. We term this phenomenon “delayed response after confirmed progression (DR)”. We also discuss the common development of second primary tumors, heterogeneous disease responses, and expanding clinical boundaries for immunotherapy use.https://www.frontiersin.org/articles/10.3389/fonc.2021.656611/fullimmunotherapyPD-1 inhibitionpseudoprogressioncutaneous squamous carcinomasecond primary tumors (SPTs) |
| spellingShingle | Annette M. Lim Annette M. Lim Karda Cavanagh Rodney J. Hicks Luke McLean Michelle S. Goh Angela Webb Danny Rischin Danny Rischin Delayed Response After Confirmed Progression (DR) and Other Unique Immunotherapy-Related Treatment Concepts in Cutaneous Squamous Cell Carcinoma Frontiers in Oncology immunotherapy PD-1 inhibition pseudoprogression cutaneous squamous carcinoma second primary tumors (SPTs) |
| title | Delayed Response After Confirmed Progression (DR) and Other Unique Immunotherapy-Related Treatment Concepts in Cutaneous Squamous Cell Carcinoma |
| title_full | Delayed Response After Confirmed Progression (DR) and Other Unique Immunotherapy-Related Treatment Concepts in Cutaneous Squamous Cell Carcinoma |
| title_fullStr | Delayed Response After Confirmed Progression (DR) and Other Unique Immunotherapy-Related Treatment Concepts in Cutaneous Squamous Cell Carcinoma |
| title_full_unstemmed | Delayed Response After Confirmed Progression (DR) and Other Unique Immunotherapy-Related Treatment Concepts in Cutaneous Squamous Cell Carcinoma |
| title_short | Delayed Response After Confirmed Progression (DR) and Other Unique Immunotherapy-Related Treatment Concepts in Cutaneous Squamous Cell Carcinoma |
| title_sort | delayed response after confirmed progression dr and other unique immunotherapy related treatment concepts in cutaneous squamous cell carcinoma |
| topic | immunotherapy PD-1 inhibition pseudoprogression cutaneous squamous carcinoma second primary tumors (SPTs) |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2021.656611/full |
| work_keys_str_mv | AT annettemlim delayedresponseafterconfirmedprogressiondrandotheruniqueimmunotherapyrelatedtreatmentconceptsincutaneoussquamouscellcarcinoma AT annettemlim delayedresponseafterconfirmedprogressiondrandotheruniqueimmunotherapyrelatedtreatmentconceptsincutaneoussquamouscellcarcinoma AT kardacavanagh delayedresponseafterconfirmedprogressiondrandotheruniqueimmunotherapyrelatedtreatmentconceptsincutaneoussquamouscellcarcinoma AT rodneyjhicks delayedresponseafterconfirmedprogressiondrandotheruniqueimmunotherapyrelatedtreatmentconceptsincutaneoussquamouscellcarcinoma AT lukemclean delayedresponseafterconfirmedprogressiondrandotheruniqueimmunotherapyrelatedtreatmentconceptsincutaneoussquamouscellcarcinoma AT michellesgoh delayedresponseafterconfirmedprogressiondrandotheruniqueimmunotherapyrelatedtreatmentconceptsincutaneoussquamouscellcarcinoma AT angelawebb delayedresponseafterconfirmedprogressiondrandotheruniqueimmunotherapyrelatedtreatmentconceptsincutaneoussquamouscellcarcinoma AT dannyrischin delayedresponseafterconfirmedprogressiondrandotheruniqueimmunotherapyrelatedtreatmentconceptsincutaneoussquamouscellcarcinoma AT dannyrischin delayedresponseafterconfirmedprogressiondrandotheruniqueimmunotherapyrelatedtreatmentconceptsincutaneoussquamouscellcarcinoma |